• Home
  • Contact Us
  • Try it!
  • Blog
  • Vizit Graphs

Follow us

Recent Posts

  • Biovista Harnesses New Kinds of Augmented and Artificial Intelligence to Address COVID-19 August 25, 2020
  • Repositioning Safety May 22, 2020
  • Artificial Intelligence firm Biovista repositions four promising therapeutics against COVID-19 April 22, 2020
  • Business Development Agent in Japan February 12, 2020
  • High Throughput Layout and Copy Paste July 5, 2019

Biovista Vizit

Biovista Vizit

  • Try it!
  • Blog
  • Vizit Graphs

C5

Mechanisms by which Eculizumab (Soliris) may benefit COVID-19 patients with respiratory distress syndrome

June 19, 2020COVID-19, Vizit Graphs
Mechanisms by which Eculizumab (Soliris) may benefit COVID-19 patients with respiratory distress syndrome

Eculizumab is a biologic therapy, a complement C5 inhibitor, and has recently shown promise in COVID-19. The graph provides an important step towards elucidating the MoA of this drug in COVID-19. Explore the live graph.

Vizit Graphs Tag Cloud

IL10 PD-1 APOPTOTIC PROCESS TNF RAS COVID-19 ALBUMIN IMMUNE RESPONSE IL2 ANGIOTENSIN II INTERFERON IMMUNITY ACE2 MYALGIA INFLAMMATION HELICOBACTER PYLORI NEUTROPHILS TMPRSS2 SARS-COV-2 CASP3 CELL PROLIFERATION CELL DIFFERENTIATION INSULIN CD4 AUTOPHAGY IFNG INFLAMMATORY RESPONSE NFKB1 CANDIDA ALBICANS PSEUDOMONAS AERUGINOSA ALZHEIMER'S DISEASE COAGULATION AGING METFORMIN ACE IL6 ESCHERICHIA COLI PARKINSON DISEASE LACTATE DEHYDROGENASE CANCER STAPHYLOCOCCUS AUREUS RHEUMATOID ARTHRITIS IL1B COGNITION LISTERIA MONOCYTOGENES

© 2021 Biovista Vizit All Rights Reserved.